Edition:
United States

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

232.32USD
1:29pm EDT
Change (% chg)

$2.83 (+1.23%)
Prev Close
$229.49
Open
$230.21
Day's High
$232.74
Day's Low
$229.53
Volume
80,220
Avg. Vol
413,428
52-wk High
$248.20
52-wk Low
$177.67

Chart for

About

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $61,470.06
Shares Outstanding(Mil.): 266.24
Dividend: 0.75
Yield (%): 1.31

Financials

  BDX.N Industry Sector
P/E (TTM): 92.05 35.24 32.21
EPS (TTM): 2.49 -- --
ROI: 1.92 14.18 13.05
ROE: 3.92 16.92 14.90

BRIEF-Becton Dickinson Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes

* BECAME AWARE OF CONCERNS ABOUT INACCURATE LEAD TEST RESULTS FROM MAGELLAN DIAGNOSTICS LEADCARE TESTING SYSTEMS

Mar 22 2018

BRIEF-Becton, Dickinson To Divest Remaining Investment In Vyaire Medical

* BD TO DIVEST REMAINING INVESTMENT IN VYAIRE MEDICAL TO FUNDS MANAGED BY APAX PARTNERS

Mar 19 2018

BRIEF-Becton Dickinson Launches Circulating Cell-Free DNA Blood Collection Tube in Western Europe

* BD LAUNCHES CIRCULATING CELL-FREE DNA BLOOD COLLECTION TUBE FOR CANCER AND NON-INVASIVE PRENATAL TESTING APPLICATIONS

Feb 20 2018

BRIEF-Becton Dickinson Files For Offering EUR 300 Mln Add. 0.368% Notes

* BECTON DICKINSON AND CO FILES FOR OFFERING EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL 0.368% NOTES DUE 2019 - SEC FILING

Feb 16 2018

BRIEF-Becton Dickinson Says Received Pre-Market Approval From FDA For BD Onclarity HPV Assay

* FDA APPROVES NEW HPV TEST THAT DETECTS AND IDENTIFIES HPV GENOTYPES THAT PUT WOMEN AT HIGH RISK FOR CERVICAL CANCER Source text for Eikon: Further company coverage:

Feb 13 2018

BRIEF-Becton Dickinson Q1 Loss Per Share $0.76

* BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER; PROVIDES FISCAL 2018 GUIDANCE UPDATED FOR INCLUSION OF BARD

Feb 06 2018

BRIEF-BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit

* BD STATEMENT ON FDA WARNING LETTER FOR PREANALYTICAL SYSTEMS BUSINESS UNIT

Jan 12 2018

BRIEF-FDA Issues Warning Letter To Becton Dickinson & Co

* FDA WARNS BECTON DICKINSON & COMPANY OF SIGNIFICANT VIOLATIONS OF THE LAW AS PART OF ONGOING INVESTIGATION INTO LEAD TESTING ISSUES‍​

Jan 11 2018

UPDATE 1-Becton Dickinson's $24 bln takeover of C R Bard set to close after China nod

* Becton had said China approval was last hurdle for deal to close

Dec 28 2017

China commerce ministry conditionally approves Becton Dickinson-C R Bard merger

BEIJING China's commerce ministry said on Thursday that it has conditionally approved a merger between U.S. medical equipment supplier Becton Dickinson and its U.S. peer C R Bard .

Dec 28 2017

Earnings vs. Estimates